Summary
23.72
-0.15
(-0.63%)
08/12/2026
Fresenius Medical Care AG & Co. KGaA (FMS)Key Facts
Performance
Historical returns1D
-0.63%
1W
-1.58%
1M
-2.99%
3M
9.61%
6M
0.89%
1Y
1.98%
5Y
-31.37%
Snapshot
Key statisticsClose
23.72
Change
-0.15
Change %
-0.63%
Open
23.79
Day Range
23.61 – 23.81
Volume
696,387
Avg Vol (20d)
799,332
Rel Vol
0.87x
52W Range
19.48 - 26.57
vs 52W High
-10.73%
vs 52W Low
21.74%
Gap
-0.75
Market Cap
USD 14.00B
Beta
0.89
Dividend Yield
2.92%
Price Chart
Advanced chartCompareLast 730 data points are shown. To view all data, Upgrade to PRO plan!
New Highs
Historical highs| Period | New Highs | From Last |
|---|---|---|
| 5-Day | 2× | -2.59% |
| 1-Month | 5× | -7.70% |
| 3-Month | 17× | -7.70% |
| 6-Month | 9× | -7.70% |
| YTD | 12× | -7.70% |
| Period | New Highs | From Last |
|---|---|---|
| 52-Week | 15× | -9.98% |
| 2-Year | 35× | -16.33% |
| 3-Year | 10× | -16.33% |
| 5-Year | 4× | -32.63% |
| 10-Year | 27× | -48.96% |
Financial SnapshotFY 2025
Full financialsRevenue
USD 19.63B
+1.5% YoY
Net Income
USD 978.37M
+32.1% YoY
EPS
3.36
+265.2% YoY
Gross Margin
25.6%
Operating Margin
9.3%
Net Margin
5.0%
EBITDA
USD 3.34B
Free Cash Flow
USD 1.77B
9.0% margin
ROE
7.4%
ROA
3.2%
Debt / Equity
0.81x
net debt USD 9.20B
Cash & Equiv.
USD 1.60B
Fundamental Ratings
MainB+
RecommendedNeutral
DCFStrong Buy
ROENeutral
ROANeutral
Debt/EquityStrong Sell
P/ENeutral
P/BBuy
Latest Earnings
- FMS reported last earnings on 2026-08-03.
- EPS of $0.66 vs $0.616 estimated — surprise $0.04.
- Revenue of $5,602M vs $5,480M estimated — surprise $121M.
News
All newsFresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS) reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in...
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
Silicon Motion Showcases Next-Generation Storage Solutions for Agentic AI Applications at FMS 2026
Silicon Motion Technology Corporation (NasdaqGS: SIMO) (âSilicon Motionâ), a global leader in designing and marketing NAND flash controllers for solid-state
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
Kioxia Showcases Flash Storage Innovations for the AI Era at FMS 2026
TOKYO--(BUSINESS WIRE)--Kioxia will showcase the innovations driving the performance, scalability, and efficiency required for next-generation AI infrastructure at FMS 2026.
Marvell to Showcase Advanced AI Memory and Storage Infrastructure Portfolio for Agentic AI Inference at FMS 2026
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $MRVL #AI--Marvell Technology, Inc. (NASDAQ: MRVL), a leader in data infrastructure semiconductor solutions, today announced it will showcase its comprehensive portfolio of AI memory and storage solutions at FMS 2026 from August 4 to 6 at the Santa Clara...
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to...
Ryder Reports Second Quarter 2026 Results
Ryder System, Inc. (NYSE: R) reported results for the three months ended June 30 as follows: This press release features multimedia. View the full release her
Fresenius Medical Care: More Favorable Patient Outcomes Will Drive Growth
Fresenius Medical Care has significant growth potential, driven by catalysts including new product rollouts and potentially improved patient outcomes. FMS's Care Delivery segment shows solid underlying earnings growth, with potential upside if patient outcomes continue to improve. Key risks include...
Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows
FMS is a defensive dialysis services provider with stable and recurring demand and regulated pricing. Profitability is recovering as FME25+ cost savings flow through the business. The stock offers attractive shareholder returns through high free cash flow, dividends, and large buybacks.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
FMS??? margin gains, HighVolumeHDF rollout and AI-driven care are boosting momentum, but reimbursement and volume risks remain.
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?
DaVita and Fresenius Medical Care are taking different paths in kidney care, but which stock offers stronger upside now? Let's dive in.
Focus Graphite Announces SEDAR+ Filing of the NI 43-101 Technical Report with the Updated Mineral Resource for the Lac Tetepisca Project
One of the Largest Identified Graphite Deposits Globally with 120.2 Mt Indicated at 10.27% Cg and 24.1 Mt Inferred at 9.88% Cg, Containing 14.7 Mt of In-Situ Graphite Ottawa, Ontario--(Newsfile Corp. - June 22, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the...
Focus Graphite Completes Final Major ESIA Technical Study, Advancing Lac Knife Toward Permitting
Hydrogeological Assessment Concludes Multi-Year Environmental Program and Supports Upcoming ESIA Submission Ottawa, Ontario--(Newsfile Corp. - June 15, 2026) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite...